Table 1.
Main characteristics of RCTs included in the meta-analysis.
| Author Year |
CRT | Patients (Number) |
Cancer type | Radiation therapy techniques | Mean hippocampus dose in HA-CRT group (Gy) | Standard CRT schedule (Gy/fraction) |
|
|---|---|---|---|---|---|---|---|
| HA-CRT | CRT | ||||||
| Rodríguez 2021 (5) |
HA-PCI, PCI | 75 | 75 | SCLC | IMRT or VMAT | 11.6 | 25/10 |
| Belderbos 2021 (8) |
84 | 84 | SCLC | IGRT | < 8.5 | ||
| Cho 2021 (18) | 48 | 58 | LS-SCLC | TOMO | NA | ||
| Wang 2021 (19) | HA-WBRT, WBRT | 27 | 20 | NSCLC with BM | IMRT or VMAT | NA | 30/10 |
| Kong 2020 (20) |
HA-PCI, PCI | 18 | 22 | LS-SCLC | VMAT | NA | 25/10 |
CRT, cranial radiation therapy; HA-CRT, hippocampal−avoidance cranial radiation therapy; SCLC, small cell lung cancer; LS-SCLC, limited-stage small cell lung cancer; HA-PCI, hippocampal−avoidance prophylactic cranial irradiation; PCI, prophylactic cranial irradiation; ES-SCLC, extensive-stage small cell lung cancer; IMRT, intensity modulated radiation therapy; VMAT, volumetric modulated arc therapy; IGRT, image-guided radiotherapy; TOMO, helical tomotherapy; NA, not available; HA-WBRT, hippocampus-avoidance whole brain radiotherapy; WBRT, whole brain radiotherapy; NSCLC, non-small cell lung cancer.